Fazlul H. Sarkar

发表

Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25

Aliccia Bollig-Fischer, Gregory Dyson, Asfar S. Azmi, 2013, BMC Systems Biology.

Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives

Fazlul H. Sarkar, Aamir Ahmad, F. Sarkar, 2012, Front. Pharmacol..

RETRACTED ARTICLE: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors

Raza Ali, Fazlul H. Sarkar, Zhiwei Wang, 2010, Breast Cancer Research and Treatment.

MI-219-Zinc Combination: a new Paradigm in MDM2 Inhibitor Based Therapy

Dajun Yang, Asfar S. Azmi, Fazlul H. Sarkar, 2010, Oncogene.

Regulation of microRNAs by Natural Agents: An Emerging Field in Chemoprevention and Chemotherapy Research

Fazlul H. Sarkar, Zhiwei Wang, D. Kong, 2010, Pharmaceutical Research.

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors

Bin Bao, Asfar S. Azmi, Fazlul H. Sarkar, 2011, Oncotarget.

Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy

Fazlul H. Sarkar, Shadan Ali, F. Sarkar, 2013, International journal of molecular sciences.

Detection of benign epithelia, prostatic intraepithelial neoplasia, and cancer regions in radical prostatectomy tissues using Raman spectroscopy

Ratna Naik, Jagdish S. Thakur, Fazlul H. Sarkar, 2010 .

Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins?

Fazlul H. Sarkar, Zhiwei Wang, D. Kong, 2011, Cancers.